DEA Extends Temporary Status of Benzimidazole-Opioids in Schedule I, Proposes Permanent Listings
The Drug Enforcement Administration is extending for one more year the temporary listing of three synthetic benzimidazole-opioid substances -- butonitazene, flunitazene and metodesnitazene -- in Schedule I of the Controlled Substances Act, it said in a notice released April 10.…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
The synthetic benzimidazole-opioids, first temporarily listed in 2022 (see 2204110029), will now remain listed in Schedule I until April 12, 2025. DEA also released a proposed rule to permanently list these synthetic benzimidazole-opioids in Schedule I, with comments due May 13. Substances may be temporarily listed under the CSA for three years.